Until last year, the majority of patients diagnosed with high risk neuroblastoma succumbed to the disease despite intensive chemotherapy and bone marrow transplantation. In 2010, the PI of this proposal reported a major improvement in survival from 46% to 66% using an antibody therapeutic. Unfortunately, we cannot predict who will respond to this treatment which is frequently accompanied by serious side effects.
University of California, San Diego
3855 Health Sciences Drive #0815
La Jolla, CA 92093
United StatesPages
- 1
- 2
